NCT03397706 2025-03-20Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesViracta Therapeutics, Inc.Phase 1/2 Completed64 enrolled 31 charts
NCT00478465 2022-05-27Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)Stanford UniversityPhase 1/2 Completed30 enrolled